Sun Pharmaceutical Industries and its subsidiary Taro Pharmaceutical have agreed to pay $200 million to resolve claims against them in the long-running multidistrict litigation accusing generic drugmakers of conspiring to fix prices and allocate markets for generic medications [1]. The settlement carries no admission of wrongdoing and remains subject to approval by the federal court overseeing the MDL in Philadelphia [1].
The underlying litigation, captioned In re Generic Pharmaceuticals Pricing Antitrust Litigation, consolidates more than 20 lawsuits originally filed beginning in 2016 [1]. Plaintiffs allege that generic drug manufacturers coordinated on pricing and divided customer accounts for at least 18 generic medications, with the alleged conspiracy dating to 2012 [1]. The MDL, seated in the Eastern District of Pennsylvania, has grown into one of the broadest antitrust proceedings in the pharmaceutical industry's history, ultimately implicating dozens of drugmakers and hundreds of generic products across parallel civil and criminal tracks.
The civil MDL has proceeded alongside criminal prosecutions brought by the Department of Justice's Antitrust Division, which has secured guilty pleas and indictments against multiple executives and companies over the same conduct. Plaintiffs in the civil cases include direct purchasers, end-payers, and state attorneys general, each pursuing separate damages tracks within the consolidated proceeding. Sun and Taro are among the larger generic manufacturers named in the litigation; Sun, incorporated in India, acquired a majority stake in Taro, an Israeli-founded company, more than a decade ago, giving the parent entity significant exposure across both entities' product portfolios.
The $200 million figure represents one of the larger individual-defendant settlements reached in the MDL to date [1]. Several other defendants have resolved their civil exposure in prior years, while others remain actively litigating. Court approval, typically requiring a finding that the settlement is fair, reasonable, and adequate, will involve notice to class members and an opportunity for objections before a final fairness hearing.
With Sun and Taro moving toward resolution, attention in the MDL shifts to remaining defendants who have not yet settled. Plaintiffs' counsel and the court have signaled interest in advancing toward trial postures for holdout defendants, which could sharpen settlement pressure across the litigation in the near term.